Guru Fundamental Report for TMO

According to Validea's guru fundamental report, Thermo Fisher Scientific (TMO) receives a 62% rating based on its John Neff-inspired Low PE Investor model, which favors firms with persistent earnings growth trading at a discount. While TMO passes tests for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence, it fails the P/E ratio and Total Return/PE tests, indicating mixed results based on Neff's value-oriented strategy.

Analysis

Thermo Fisher Scientific Inc. (TMO), a large-cap growth stock within the Medical Equipment & Supplies sector, has been evaluated by Validea's Low PE Investor model, inspired by John Neff's strategy, yielding a rating of 62%. This score, while indicating some positive attributes, falls short of the 80% threshold typically signifying notable interest from this specific investment model. The analysis reveals a dichotomy: TMO demonstrates robust operational health, passing criteria for EPS growth, future EPS growth, sales growth, free cash flow, and EPS persistence. However, it fails on two key valuation metrics central to Neff's philosophy – the P/E Ratio and the Total Return/PE ratio. This suggests that while TMO exhibits strong fundamental growth characteristics, its current market price does not present the discounted valuation relative to earnings growth and dividend yield that the Neff strategy prioritizes, leading to a moderate overall score from this value-centric perspective.

Key Decisions for Investors

• Investors strictly following John Neff's value-oriented, low P/E strategy may find TMO's current valuation metrics, specifically its P/E ratio and Total Return/PE, uncompelling despite its demonstrated strengths in earnings and sales growth.
• Considering TMO passes criteria for EPS growth, future EPS growth, sales growth, and free cash flow, growth-focused investors might see fundamental strength, but should recognize it does not align with the value parameters of the assessed Neff model.
• The 62% rating suggests TMO is not a strong buy candidate under this specific value strategy; therefore, investors employing similar methodologies should exercise caution or seek more attractive valuations, while others might use this as one input among broader due diligence.